MiMedx Group Inc. (NASDAQ:MDXG)’s share price fell 2.3% during trading on Monday . The stock traded as low as $6.94 and last traded at $7.07, with a volume of 667,715 shares trading hands. The stock had previously closed at $7.24.

Several brokerages recently commented on MDXG. Brean Capital reaffirmed a “buy” rating on shares of MiMedx Group in a research note on Wednesday, June 29th. Zacks Investment Research raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $10.89.

The firm has a market capitalization of $781.30 million and a PE ratio of 33.65. The firm has a 50 day moving average price of $7.61 and a 200 day moving average price of $7.87.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by $0.02. During the same period in the prior year, the business posted $0.05 earnings per share. The business had revenue of $57 million for the quarter, compared to analyst estimates of $56.49 million. MiMedx Group’s quarterly revenue was up 25.5% on a year-over-year basis. Equities research analysts predict that MiMedx Group Inc. will post $0.23 earnings per share for the current year.

In other MiMedx Group news, COO William Charles Taylor sold 24,333 shares of the stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $7.52, for a total transaction of $182,984.16. Following the completion of the sale, the chief operating officer now directly owns 616,078 shares of the company’s stock, valued at approximately $4,632,906.56. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A hedge fund recently raised its stake in MiMedx Group stock. Wells Fargo & Company MN raised its position in shares of MiMedx Group Inc. (NASDAQ:MDXG) by 19.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,041,546 shares of the company’s stock after buying an additional 169,102 shares during the period. Wells Fargo & Company MN owned 0.96% of MiMedx Group worth $9,759,000 as of its most recent SEC filing.

MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.